The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be recruited from the community. Stage one aims to identify the Most Effective Dose (MEDmg) of oral cannabidiol for reducing cannabis use over four treatment weeks. Stage two will determine whether the MED identified in stage 1 can offer an effective treatment for cannabis dependence.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
82
Clinical Psychopharmacology Unit
London, United Kingdom
Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine (THC-COOH:creatinine)
This study has two stages. This is the primary endpoint criteria for stage 1.
Time frame: up to 4 weeks
Number of days abstinent from cannabis
This study has two stages. This is the primary endpoint criteria for stage 1.
Time frame: up to 4 weeks
Diagnostic and Statistical Manual- 5 (DSM-5) criteria for moderate cannabis dependence
This study has two stages. This is the primary endpoint criteria for stage 2.
Time frame: up to 4 weeks
Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine(THC-COOH:creatinine) below 50ng/ml
This study has two stages. This is the primary endpoint criteria for stage 2.
Time frame: week 4
Psychological Wellbeing, Cognition and Endocannabinoids
Psychological Wellbeing, Cognition and Endocannabinoids will be measured by questionnaire methods, neuropsychological testing and biological samples.
Time frame: Up to 28 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.